Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2016 | ASCEND-1 and ASCEND-2: Ceritinib for ALK-rearranged NSCLC and baseline brain metastases

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses results from ASCEND-1 and ASCEND-2, two non-randomized phase 1/2 multicenter, open-label, single-arm trials evaluating the efficacy of ceritinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, in patients with pretreated, ALK-rearranged non-small cell lung cancer (NSCLC) and baseline brain metastases.